India
· Delayed Price · Currency is INR AstraZeneca Pharma India Statistics
Total Valuation
AstraZeneca Pharma India has a market cap or net worth of INR 158.42 billion. The enterprise value is 153.63 billion.
| Market Cap | 158.42B |
| Enterprise Value | 153.63B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Jul 5, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 4.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 97.94, with an EV/FCF ratio of 1,846.47.
| EV / Earnings | 187.53 |
| EV / Sales | 10.35 |
| EV / EBITDA | 97.94 |
| EV / EBIT | 112.73 |
| EV / FCF | 1,846.47 |
Financial Position
The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.25 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | 2.06 |
| Interest Coverage | 136.28 |
Financial Efficiency
Return on equity (ROE) is 12.28% and return on invested capital (ROIC) is 12.56%.
| Return on Equity (ROE) | 12.28% |
| Return on Assets (ROA) | 7.27% |
| Return on Capital (ROIC) | 12.56% |
| Revenue Per Employee | 18.56M |
| Profits Per Employee | 1.02M |
| Employee Count | 940 |
| Asset Turnover | 1.27 |
| Inventory Turnover | 2.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.99% in the last 52 weeks. The beta is 0.30, so AstraZeneca Pharma India's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +34.99% |
| 50-Day Moving Average | 7,264.98 |
| 200-Day Moving Average | 6,344.99 |
| Relative Strength Index (RSI) | 31.33 |
| Average Volume (20 Days) | 25,457 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca Pharma India had revenue of INR 14.85 billion and earned 819.20 million in profits. Earnings per share was 32.77.
| Revenue | 14.85B |
| Gross Profit | 6.60B |
| Operating Income | 1.36B |
| Pretax Income | 1.11B |
| Net Income | 819.20M |
| EBITDA | 1.54B |
| EBIT | 1.36B |
| Earnings Per Share (EPS) | 32.77 |
Balance Sheet
The company has 4.97 billion in cash and 171.20 million in debt, giving a net cash position of 4.80 billion.
| Cash & Cash Equivalents | 4.97B |
| Total Debt | 171.20M |
| Net Cash | 4.80B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.79B |
| Book Value Per Share | 271.70 |
| Working Capital | 5.92B |
Cash Flow
In the last 12 months, operating cash flow was 168.70 million and capital expenditures -85.50 million, giving a free cash flow of 83.20 million.
| Operating Cash Flow | 168.70M |
| Capital Expenditures | -85.50M |
| Free Cash Flow | 83.20M |
| FCF Per Share | n/a |
Margins
Gross margin is 44.46%, with operating and profit margins of 9.18% and 5.52%.
| Gross Margin | 44.46% |
| Operating Margin | 9.18% |
| Pretax Margin | 7.45% |
| Profit Margin | 5.52% |
| EBITDA Margin | 10.36% |
| EBIT Margin | 9.18% |
| FCF Margin | 0.56% |
Dividends & Yields
AstraZeneca Pharma India does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 73.24% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.03% |
| Earnings Yield | 0.52% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |